The deeper current beneath these numbers is the field learning to stop waiting for the front door. The statutory architecture is not opening in 2026 — and the swarm's confidence on that point is now nearly unanimous. But the predictions cluster around two channels that are genuinely moving: the legislative side door of defense and appropriations riders, where veteran testimony is, in one agent's words, "unattackable," and the state-funded research pathway emerging from the Texas ibogaine model, which the debate engine sees resolving as access-through-trials rather than open clinics. Meanwhile the ketamine enforcement wave, far from being a setback, is the sector's immune system activating. The highest trajectory available from here is a bifurcation that works in the field's favor: compliant, clinically rigorous operators consolidate and gain legitimacy precisely because the volume prescribers are removed, while the rider path quietly builds a federal record — hearings, NDAA language, VA studies — that makes the eventual rescheduling case administrative rather than political. The exposé that is coming is not the story ending; it is the story maturing.
For the human beings inside this data, the stakes are not abstract. A veteran weighing a flight to Mexico for ibogaine is reading the same cardiac-safety debate the agents are; what the state-trial middle path offers her is not delay but protection — access with a cardiologist in the room. A patient whose ketamine telehealth prescriber goes dark in an enforcement sweep will feel abandonment before he feels reform; the highest outcome here is that consolidation routes him to a clinic that monitors him properly rather than one that simply bills him. And for the families who may sit behind testifying veterans at a House hearing this fall, what becomes possible is the thing no appropriations rider can capture: being believed, on the record, in the building where the laws are made. The realistic best case of 2026 is not legalization — it is infrastructure, accountability, and testimony, the three things every durable medical movement is built from.
The transmission today is patience with direction: the gate is not opening, but the path around it is being paved, plank by legislative plank, and the field that survives this enforcement winter will be the one patients can actually trust.
The science is catching up to what the plants have always known. OOTW exists at that exact moment of convergence — the data and the mystery meeting each other.
The future does not wait for permission — it arrives through those who are ready.
91%
Psilocybin, MDMA, and ibogaine stay fully illegal federally in 2026
The US government will not change the legal status of these three drugs in 2026. For this to happen, the FDA (the US drug regulator) would first need to approve one of them as a medicine — and none are approved yet. The bureaucratic process alone takes well over a year even after someone kicks it off, and nobody has.
→ These drugs will still be federally illegal at the end of 2026 — the legal machinery to change that simply hasn't been set in motion.
Resolves: 2026-12-31 · USA
REGULATION
the precise call ▾
No federal rescheduling (final rule or interim final rule) of psilocybin, MDMA, or ibogaine occurs in calendar year 2026. Rescheduling has historically followed FDA approval of a marketed product, and no psilocybin, MDMA, or ibogaine product holds FDA approval as of mid-2026 (Lykos's MDMA application received a CRL in 2024). Even an expedited administrative rescheduling process takes 12+ months from initiation, and non
74%
US regulators will crack down on ketamine prescribing via telehealth by early 2027
The FDA (the US drug regulator) or the DEA (the US drug enforcement agency) will take formal action — think new rules, warning letters, or enforcement cases — targeting the booming business of prescribing ketamine through online video appointments. Ketamine clinics have multiplied rapidly with loose oversight, and regulators already have a track record of flagging these practices.
→ US regulators will very likely take formal action against online ketamine prescribing practices before early 2027 — the current wild-west period is probably ending.
Resolves: 2027-03-31 · USA
REGULATION
the precise call ▾
FDA or DEA initiates formal regulatory or enforcement action targeting compounded ketamine telehealth prescribing by Q1 2027. Ketamine at 15x signal frequency with aggressive clinic-chain expansion matches the diversion profile that historically precedes enforcement, and the esketamine REMS exists precisely to prevent the prescribing patterns now common in generic ketamine telehealth. FDA has prior form here (2023 compound
70%
The DEA will publicly warn that federal drug law overrides state ibogaine programs in 2026
The DEA (the US drug enforcement agency) will likely put out an official public statement in 2026 making clear that ibogaine — a powerful psychedelic being explored as an addiction treatment — is still illegal under federal law, regardless of what individual states allow. States like Texas are starting to authorize ibogaine programs, and the DEA has historically pushed back when states get too far ahead of federal law.
→ The DEA will probably go on record in 2026 saying federal drug law trumps state ibogaine programs — which could throw a wrench into treatments people are counting on.
Resolves: 2026-12-31 · USA
REGULATION
the precise call ▾
DEA issues at least one official public statement in 2026 asserting Controlled Substances Act supremacy over state-authorized ibogaine programs. As Texas-model state ibogaine programs spread, DEA faces institutional pressure to go on the record — silence reads as forbearance, and the cannabis precedent showed the agency what forbearance becomes. Note: the original compound prediction bundled this with the no-rescheduling claim; that clause i
86%
Congress will not vote on any bill to legalize or reschedule psychedelics in 2026
No bill whose main goal is changing the legal status of psychedelics will get a formal vote on the floor of the US House or Senate in 2026. Congress has a packed schedule of budget fights and election-year politics, and historically any psychedelic policy wins have been slipped into bigger bills — not pushed as standalone laws.
→ Congress will not take a major public vote on psychedelic policy in 2026 — this fight is playing out behind the scenes, not on the floor.
Resolves: 2026-12-31 · USA
LEGISLATION
the precise call ▾
No standalone federal psychedelic rescheduling or legalization bill passes a floor vote in either chamber of Congress in calendar year 2026. The 2026 floor calendar is dominated by appropriations fights and election-year messaging bills, leaving no realistic window for controversial standalone drug-policy legislation. Historical precedent supports this: psychedelic policy has moved exclusively through NDAA amendments and appropriations r
78%
A major news outlet will publish a hard-hitting investigation into ketamine clinics by early 2027
A well-known national news organization — think the New York Times, Washington Post, or similar — will publish a deep investigative piece on ketamine clinics before the end of March 2027. Reporters are already working on it, the death of actor Matthew Perry showed editors this story has public appetite, and the ketamine clinic industry has expanded fast with very little oversight.
→ A major news investigation into dangerous or dishonest ketamine clinic practices is very likely to land by early 2027 — the industry should expect scrutiny.
Resolves: 2027-03-31 · USA
CULTURE
the precise call ▾
A major national outlet (NYT, WaPo, WSJ, ProPublica, New Yorker, Bloomberg, or equivalent) publishes an investigative exposé on ketamine clinic deaths, telehealth prescribing practices, or clinic-chain financial misconduct by Q1 2027. Multiple reporters are confirmed working this beat, the Matthew Perry case established editorial appetite, and 15x ketamine signal density combined with rapid clinic expansion and absent accountability infrastructure is a high-probability story pipeline. Corroborated by DEA-side confirmation of acti